Jounce Therapeutics Stock Slides On Disappointing Data, Wells Fargo Downgrades
Janney Initiates Galapagos At Buy, Sees Fair Value Of Shares At $64
Downside Risk In Sarepta Shares Greater Than Upside Potential, Janney Says
Roth Capital On PTC Therapeutics: 'Staying On The Sidelines' Until Regulatory Clarity